Why the study?
How can high-risk patients with hypertrophic cardiomyopathy be distinguished from low-risk patients to appropriately target prophylactic AICD or amiodarone therapy?
Population
Patients with hypertrophic cardiomyopathy (HCM)
Design
Review
Key result
Risk stratification for prophylactic therapies like AICDs in hypertrophic cardiomyopathy is essential given the disease's 0.2% prevalence and approximately 1% annual mortality rate.
Authors
Loading...
Emphasizes targeted AICD use in HCM to minimize complications; leaves open need for validated risk markers.
How can high-risk patients with hypertrophic cardiomyopathy be distinguished from low-risk patients to appropriately target prophylactic AICD or amiodarone therapy?
Risk stratification in hypertrophic cardiomyopathy is crucial to appropriately target AICD therapy and avoid high lifetime risks of device-related complications in low-risk patients.
M. Frenneaux (2004) conducted a review in Hypertrophic cardiomyopathy. Risk stratification for prophylactic therapies like AICDs in hypertrophic cardiomyopathy is essential given the disease's 0.2% prevalence and approximately 1% annual mortality rate.